Sign in Subscribe

combination

A collection of 67 issues

Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer A phase 1/2 trial testing copanlisib (a PIK3CA inhibitor) combined with nivolumab in metastatic microsatellite stable CRC did not meet its primary endpoint, with 0 of 17 PIK3CA-wildtype

Vactosertib Plus Pembrolizumab Shows Manageable Safety in Non-MSI-High mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Vactosertib Plus Pembrolizumab Shows Manageable Safety in Non-MSI-High mCRC A phase Ib/IIa study of vactosertib combined with pembrolizumab in non-MSI-high metastatic colorectal cancer demonstrated a manageable safety profile, with secondary outcomes including objective response rate, progression-free survival, and overall survival. (Nature

Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer

Skip to content The CRC Digest ▸ TREATMENT Long-term outcomes reported for neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer A multicentre study followed patients treated with bevacizumab combined with chemoradiation before surgery for locally advanced rectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute

BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA BREAKWATER trial compares encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer This randomized study evaluated targeted therapy combinations specifically for patients with BRAF V600E mutations, a subtype associated with poorer outcomes. (Annals of Oncology) This

CRC Research Finding

Skip to content The CRC Digest ◇ Review examines anti-VEGF plus checkpoint inhibitor combinations in GI cancers A narrative review synthesizes preclinical and clinical data on combining anti-VEGF agents with immune checkpoint inhibitors across gastrointestinal cancers, including colorectal cancer, with emphasis on optimal sequencing strategies. (Discov Oncol) This content is informational

Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination

Skip to content The CRC Digest Clinical complete response in MSS/KRAS-mutant mCRC with immunotherapy combination Case report describes a 62-year-old woman with KRAS p.G12D, pMMR/MSS metastatic sigmoid colon cancer who achieved sustained regression with serplulimab, bevacizumab, and XELOX, with CEA declining from 3458.2 to 1812.84

RAS mutation linked to early progression in liver metastases conversion therapy

Skip to content The CRC Digest RAS mutation linked to early progression in liver metastases conversion therapy Retrospective study of 194 patients with initially unresectable, pMMR colorectal liver metastases found that RAS mutation status was associated with early progression or recurrence after conversion therapy. (Front Surg) This content is informational

Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Metronomic chemotherapy plus regorafenib tested in treatment-resistant metastatic colorectal cancer — ESMO Gastrointestinal Oncology The REPROGRAM-01 single-arm phase II trial tested regorafenib combined with metronomic capecitabine, cyclophosphamide, and aspirin in refractory metastatic colorectal cancer. This approach aims to improve outcomes in heavily pre-treated patients

Testing immunotherapy combination in MSS metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Testing immunotherapy combination in MSS metastatic colorectal cancer — Clinical Colorectal Cancer A Phase II study of pembrolizumab plus capecitabine and bevacizumab for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. Most colorectal cancers are MSS/pMMR and don't respond well to

Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Encorafenib and cetuximab re-challenge combined with nivolumab in BRAF-mutated colorectal cancer — Clinical Colorectal Cancer A case report from the AGMT mCRC Registry documented successful encorafenib and cetuximab re-challenge combined with nivolumab in BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer. If you have BRAF